LLY - Eli Lilly & Co Stock Price, Fair Value and News

778.61USD+0.84 (+0.11%)Delayed as of 08 May 2024, 12:59 pm ET

Market Summary

USD778.61+0.84

Delayedas of 08 May 2024, 12:59 pm

0.11%

LLY Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

LLY Stock Price

View Fullscreen

LLY RSI Chart

LLY Valuation

Market Cap

739.0B

Price/Earnings (Trailing)

120.39

Price/Sales (Trailing)

20.57

EV/EBITDA

83.39

Price/Free Cashflow

201.06

LLY Price/Sales (Trailing)

LLY Profitability

EBT Margin

21.04%

Return on Equity

47.59%

Return on Assets

9.6%

Free Cashflow Yield

0.5%

LLY Fundamentals

LLY Revenue

Revenue (TTM)

35.9B

Rev. Growth (Yr)

25.98%

Rev. Growth (Qtr)

-6.26%

LLY Earnings

Earnings (TTM)

6.1B

Earnings Growth (Yr)

66.77%

Earnings Growth (Qtr)

2.43%

Breaking Down LLY Revenue

52 Week Range

419.80781.13

(Low)(High)

Last 7 days

-0.4%

Last 30 days

-0.8%

Last 90 days

7.2%

Trailing 12 Months

79.7%

How does LLY drawdown profile look like?

LLY Financial Health

Current Ratio

1.35

Debt/Equity

1.9

Debt/Cashflow

0.15

LLY Investor Care

Dividend Yield

0.87%

Dividend/Share (TTM)

6.8

Shares Dilution (1Y)

0.12%

Diluted EPS (TTM)

6.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	35.9B	0	0	0
2023	27.7B	29.5B	32.1B	34.1B
2022	29.3B	29.1B	29.2B	28.5B
2021	25.5B	26.7B	27.8B	28.3B
2020	23.1B	22.9B	23.2B	24.5B
2019	21.6B	21.7B	21.8B	22.3B
2018	20.4B	20.9B	21.3B	21.5B
2017	20.9B	20.6B	20.3B	20.0B
2016	20.2B	20.6B	20.8B	21.2B
2015	19.6B	19.6B	19.7B	20.0B
2014	22.2B	21.2B	20.3B	19.6B
2013	22.6B	22.9B	23.3B	23.1B
2012	24.0B	23.4B	22.7B	22.6B
2011	23.4B	23.9B	24.4B	24.3B
2010	22.3B	22.7B	22.8B	23.1B
2009	20.6B	20.8B	21.1B	21.8B
2008	0	19.2B	19.8B	20.4B
2007	0	0	0	18.6B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Eli Lilly & Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	alvarez ralph	acquired	12,012	750	16.00	-
Apr 15, 2024	sulzberger gabrielle	acquired	9,760	750	13.00	-
Apr 15, 2024	johnson kimberly h	acquired	9,760	750	13.00	-
Apr 15, 2024	luciano juan r	acquired	15,015	750	20.00	-
Apr 15, 2024	hedley mary lynne	acquired	9,760	750	13.00	-
Mar 18, 2024	hedley mary lynne	acquired	9,914	762	13.00	-
Mar 18, 2024	luciano juan r	acquired	14,490	762	19.00	-
Mar 18, 2024	johnson kimberly h	acquired	9,914	762	13.00	-
Mar 18, 2024	sulzberger gabrielle	acquired	9,914	762	13.00	-
Mar 18, 2024	alvarez ralph	acquired	11,439	762	15.00	-

Which funds bought or sold LLY recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 06, 2024	SUMMITRY LLC	new	-	265,285	265,285	0.01%
May 06, 2024	BANQUE PICTET & CIE SA	reduced	-3.26	11,020,900	48,886,200	0.46%
May 06, 2024	CAPITAL CITY TRUST CO/FL	reduced	-8.11	117,181	634,814	0.18%
May 06, 2024	Hartford Funds Management Co LLC	reduced	-12.73	142,868	1,012,730	0.10%
May 06, 2024	Empowered Funds, LLC	added	8.29	7,675,860	24,915,700	0.45%
May 06, 2024	Advisors Capital Management, LLC	added	22.64	2,200,000	5,656,000	0.10%
May 06, 2024	Hardman Johnston Global Advisors LLC	added	40.92	291,074	621,590	0.02%
May 06, 2024	GRANDFIELD & DODD, LLC	reduced	-2.36	522,982	2,248,780	0.14%
May 06, 2024	Broderick Brian C	new	-	1,979,910	1,979,910	0.42%
May 06, 2024	SG Americas Securities, LLC	added	632	125,842,000	140,181,000	0.67%

Are Funds Buying or Selling LLY?

Are funds buying LLY calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LLY

No. of Funds

Unveiling Eli Lilly & Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	7.54%	71,604,696	SC 13G/A
Feb 09, 2024	pnc financial services group, inc.	5.43%	51,540,105	SC 13G/A
Jan 29, 2024	blackrock inc.	6.8%	64,376,027	SC 13G/A
Jan 26, 2024	lilly endowment inc	10.51%	99,768,810	SC 13G/A
Feb 10, 2023	pnc financial services group, inc.	5.25%	51,829,873	SC 13G/A
Feb 09, 2023	vanguard group inc	7.73%	73,429,863	SC 13G/A
Feb 01, 2023	blackrock inc.	6.9%	65,467,793	SC 13G/A
Jan 25, 2023	lilly endowment inc	10.83%	102,948,810	SC 13G/A
Feb 11, 2022	pnc financial services group, inc.	5.42%	51,888,455	SC 13G/A
Feb 09, 2022	vanguard group inc	7.24%	69,261,754	SC 13G/A

Recent SEC filings of Eli Lilly & Co

View All Filings

Date Filed	Form Type	Document
May 03, 2024	SD	SD
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 16, 2024	4	Insider Trading
Apr 11, 2024	PX14A6G	PX14A6G
Apr 04, 2024	PX14A6G	PX14A6G

Peers (Alternatives to Eli Lilly & Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.6B	-2.43%	-8.39%	9.3	4.18	5.68%	202.39%
MRK	330.2B	61.4B	1.86%	10.13%	143.19	5.38	6.11%	-82.30%
AMGN	161.1B	29.5B	11.28%	28.04%	42.82	5.46	12.76%	-52.47%
PFE	156.8B	46.5B	4.16%	-28.19%	-112.94	3.37	42.59%	-114.62%
GILD	81.5B	27.1B	-5.96%	-16.75%	14.39	3.01	-0.60%	23.36%
TEVA	15.6B	15.8B	-2.04%	54.08%	-27.14	0.99	6.17%	76.47%
MID-CAP
ALKS	4.2B	1.7B	-5.86%	-20.45%	9.58	2.41	54.01%	364.56%
PRGO	4.1B	4.6B	-3.95%	-16.22%	-533.77	0.9	-0.06%	94.55%
BHC	2.7B	9.0B	-28.82%	23.71%	-5.97	0.3	10.01%	-27.45%
AMPH	2.1B	644.4M	2.42%	17.52%	14.96	3.19	29.14%	50.51%
SMALL-CAP
TLRY	1.5B	743.2M	-23.46%	-28.42%	-4.38	2.07	24.65%	80.36%
TXMD	23.2M	1.3M	-9.05%	-48.20%	-2.26	17.8	-98.14%	-109.18%
ACRX	17.0M	-	-15.25%	35.14%	-0.92	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	31.03%	-94.02%	-0.19	0.14	80.00%	43.08%
ACOR	1.1M	117.6M	-57.29%	-90.96%	0	0.01	-0.79%	-283.60%

Eli Lilly & Co News

Latest updates

Eli Lilly & Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-6.3%	8,768	9,353	9,499	8,312	6,960	7,302	6,942	6,488	7,810	8,000	6,773	6,740	6,806	7,440	5,741	5,499	5,860	6,114	5,477	5,637	5,092
S&GA Expenses	1.4%	1,952	1,925	1,804	1,925	1,749	1,643	1,614	1,625	1,558	1,592	1,578	1,686	1,576	1,554	1,569	1,449	1,550	1,698	1,412	1,586	1,517
R&D Expenses	-	-	-	-	2,357	1,985	1,996	1,803	1,782	1,610	1,898	1,705	1,655	1,672	1,729	1,465	1,390	1,392	1,581	1,381	1,402	1,231
EBITDA Margin	7.2%	0.25*	0.24*	0.24*	0.30*	0.28*	0.29*	0.28*	0.27*	0.29*	0.27*	0.30*	0.32*	-	-	-	-	-	-	-	-	-
Income Taxes	-8.1%	293	319	485	326	185	159	114	138	151	114	135	204	121	352	229	232	223	167	152	139	170
Earnings Before Taxes	1.1%	2,536	2,509	427	2,089	1,530	2,096	1,566	1,091	2,054	1,840	1,245	1,594	1,476	2,469	1,437	1,644	1,680	1,663	1,406	1,466	731
EBT Margin	9.6%	0.21*	0.19*	0.19*	0.25*	0.23*	0.24*	0.22*	0.21*	0.23*	0.22*	0.24*	0.26*	-	-	-	-	-	-	-	-	-
Net Income	2.4%	2,243	2,190	-57.40	1,763	1,345	1,938	1,452	953	1,903	1,726	1,110	1,390	1,355	2,117	1,208	1,412	1,457	1,496	1,254	1,327	4,242
Net Income Margin	11.2%	0.17*	0.15*	0.16*	0.22*	0.21*	0.22*	0.21*	0.20*	0.21*	0.20*	0.22*	0.23*	-	-	-	-	-	-	-	-	-
Free Cashflow	473.8%	1,166	-311	2,190	632	1,731	1,663	2,217	1,183	2,523	2,262	1,631	1,776	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-0.1%	63,944	64,006	57,916	54,814	53,163	49,490	47,462	47,064	46,919	48,806	48,187	47,809	46,838	46,633	43,946	41,967	41,103	39,286	37,893	38,666	38,007
Current Assets	-2.1%	25,189	25,727	23,007	21,332	20,811	18,035	17,640	17,115	16,965	18,452	17,808	17,296	16,605	17,462	16,240	14,582	13,994	13,710	12,662	13,455	12,598
Cash Equivalents	-12.7%	2,460	2,819	2,381	2,695	3,546	2,067	2,617	2,623	2,459	3,819	3,788	3,220	3,002	3,657	3,595	2,365	1,699	2,338	-	2,290	2,036
Inventory	5.7%	6,102	5,773	4,901	4,799	4,545	4,310	3,831	3,899	3,893	3,886	3,907	3,825	3,661	3,980	3,555	3,314	3,102	3,191	3,101	3,181	3,055
Net PPE	5.5%	13,624	12,914	11,863	11,277	10,546	10,144	9,311	9,128	9,103	8,985	8,920	8,856	8,630	8,682	8,281	7,981	7,898	7,873	7,802	7,848	7,780
Goodwill	0.0%	4,940	4,940	4,085	4,079	4,073	4,073	3,892	3,892	3,892	3,892	3,884	3,884	3,877	3,767	3,726	3,723	3,779	3,679	3,773	3,820	3,856
Current Liabilities	-31.9%	18,598	27,293	21,998	18,915	16,010	17,138	15,653	15,621	13,386	15,053	13,682	15,093	11,714	12,482	11,977	11,989	12,610	11,775	10,829	11,855	11,236
Long Term Debt	34.1%	24,560	18,321	17,924	18,158	18,881	14,738	14,144	14,692	15,153	15,346	15,522	14,737	16,200	16,587	16,335	15,064	13,982	13,818	13,662	13,718	13,610
LT Debt, Non Current	34.1%	24,560	18,321	17,924	18,158	18,881	14,738	14,144	14,692	15,153	15,346	15,522	14,737	16,200	16,587	16,335	15,064	13,982	13,818	13,662	13,718	13,610
Shareholder's Equity	18.9%	12,812	10,772	11,220	11,064	144	10,043	91.00	8,556	594	596	7.00	6,669	6,899	15.00	7,154	15.00	6.00	4,920	3,383	6,535	5,757
Retained Earnings	21.7%	12,554	10,312	10,310	10,369	10,639	10,043	10,007	8,556	9,369	8,959	9,639	8,530	9,181	7,830	7,154	6,617	5,879	4,920	4,982	4,318	4,879
Additional Paid-In Capital	-3.3%	7,010	7,250	7,160	6,949	6,793	6,921	6,829	6,746	6,656	6,833	6,758	6,669	6,579	6,779	6,699	6,629	6,556	6,685	6,609	6,535	5,757
Accumulated Depreciation	1.2%	11,235	11,099	10,768	10,632	10,486	10,233	10,074	10,120	10,138	9,977	9,963	9,842	9,643	9,571	9,601	9,297	9,142	9,162	9,055	8,956	8,792
Shares Outstanding	0.1%	901	900	900	900	901	902	901	902	904	907	907	908	-	-	-	-	-	-	-	-	-
Minority Interest	-7.2%	85.00	92.00	87.00	86.00	105	126	96.00	115	131	176	197	219	201	184	169	179	118	92.00	80.00	77.00	85.00
Float	-	-	-	-	398,291	-	-	-	274,342	-	-	-	193,649	-	-	-	138,907	-	-	-	93,167	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	473.8%	1,166	-311	2,190	632	1,731	1,663	2,217	1,183	2,523	2,262	1,631	1,776	1,697	1,815	1,807	2,495	382	1,964	1,510	1,052	311
Share Based Compensation	32.6%	159	120	216	162	131	93.00	85.00	92.00	101	75.00	90.00	92.00	86.00	88.00	72.00	77.00	72.00	82.00	76.00	80.00	76.00
Cashflow From Investing	59.7%	-1,177	-2,924	-3,080	-459	-688	-943	-955	-826	-1,037	-484	-616	-483	-1,283	-674	-313	-210	-1,060	-41.40	-423	61.00	-7,678
Cashflow From Financing	-108.8%	-311	3,545	572	-1,033	412	-1,141	-1,263	-123	-2,878	-1,526	-463	-1,083	-1,058	-1,291	-279	-1,673	107	-1,113	-1,692	-885	1,368
Dividend Payments	14.8%	1,169	1,018	1,016	1,018	1,017	884	882	884	886	773	770	768	775	670	672	674	671	587	587	598	637
Buy Backs	-	-	-	-	-	750	-	-	-	1,500	750	-	500	-	-	-	-	500	300	600	-	3,500

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

LLY Income Statement

2024-03-31

Consolidated Condensed Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue (Note 2)	$ 8,768.0	$ 6,960.0
Costs, expenses, and other:
Cost of sales	1,673.5	1,626.7
Research and development	2,522.8	1,985.1
Marketing, selling, and administrative	1,952.2	1,749.2
Acquired in-process research and development (Note 3)	110.5	105.0
Other–net, (income) expense (Note 11)	(27.1)	(35.7)
Costs, expenses, and other	6,231.9	5,430.3
Income before income taxes	2,536.1	1,529.7
Income taxes (Note 7)	293.2	184.8
Net income	$ 2,242.9	$ 1,344.9
Earnings per share:
Basic (in dollars per share)	$ 2.49	$ 1.49
Diluted (in dollars per share)	$ 2.48	$ 1.49
Shares used in calculation of earnings per share:
Basic (in shares)	900.8	901.0
Diluted (in shares)	903.8	903.3

LLY Balance Sheet

2024-03-31

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current Assets
Cash and cash equivalents (Note 6)	$ 2,460.2	$ 2,818.6
Short-term investments (Note 6)	126.1	109.1
Accounts receivable, net of allowances of $14.3 (2024) and $14.8 (2023)	7,885.6	9,090.5
Other receivables	2,127.9	2,245.7
Inventories (Note 5)	6,101.8	5,772.8
Prepaid expenses	6,348.6	5,540.8
Other current assets	138.6	149.5
Total current assets	25,188.8	25,727.0
Investments (Note 6)	3,086.9	3,052.2
Goodwill	4,939.6	4,939.7
Other intangibles, net	6,762.2	6,906.6
Deferred tax assets	5,633.9	5,477.3
Property and equipment, net of accumulated depreciation of $11,235.0 (2024) and $11,099.3 (2023)	13,624.0	12,913.6
Other noncurrent assets	4,708.1	4,989.9
Total assets	63,943.5	64,006.3
Current Liabilities
Short-term borrowings and current maturities of long-term debt	1,651.5	6,904.5
Accounts payable	2,473.7	2,598.8
Employee compensation	844.2	1,650.4
Sales rebates and discounts	9,429.6	11,689.0
Dividends payable	0.0	1,169.2
Other current liabilities	4,199.1	3,281.3
Total current liabilities	18,598.1	27,293.2
Noncurrent Liabilities
Long-term debt	24,559.9	18,320.8
Accrued retirement benefits (Note 8)	1,427.9	1,438.8
Long-term income taxes payable	4,189.4	3,849.2
Other noncurrent liabilities	2,270.8	2,240.6
Total noncurrent liabilities	32,448.0	25,849.4
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders' Equity
Common stock	594.2	593.6
Additional paid-in capital	7,009.5	7,250.4
Retained earnings	12,553.9	10,312.3
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 10)	(4,299.5)	(4,327.0)
Cost of common stock in treasury	(32.7)	(44.2)
Total Eli Lilly and Company shareholders' equity	12,812.2	10,771.9
Noncontrolling interests	85.2	91.8
Total equity	12,897.4	10,863.7
Total liabilities and equity	$ 63,943.5	$ 64,006.3

About Eli Lilly & Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

CEO	Mr. David A. Ricks
WEBSITE	lilly.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	39000

Eli Lilly & Co Frequently Asked Questions

What is the ticker symbol for Eli Lilly & Co? What does LLY stand for in stocks?

LLY is the stock ticker symbol of Eli Lilly & Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eli Lilly & Co (LLY)?

As of Tue May 07 2024, market cap of Eli Lilly & Co is 739.01 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers. The fair value of Eli Lilly & Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Eli Lilly & Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LLY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Eli Lilly & Co a good stock to buy?

The fair value guage provides a quick view whether LLY is over valued or under valued. Whether Eli Lilly & Co is cheap or expensive depends on the assumptions which impact Eli Lilly & Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LLY.

What is Eli Lilly & Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue May 07 2024, LLY's PE ratio (Price to Earnings) is 120.39 and Price to Sales (PS) ratio is 20.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LLY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eli Lilly & Co's stock?

In the past 10 years, Eli Lilly & Co has provided 0.319 (multiply by 100 for percentage) rate of return.